A Study on Expression of P53 in Surface Epithelial Ovarian Tumours
Aims and Objectives: (1) To perform and interpret p53 immunostaining on the diagnosed malignant surface epithelial ovarian tumours. (2) To correlate expression of p53 with histological type of malignancy. Materials and Methods: A 2-year prospective study was done i.e., from October 2011 to September 2013 on ‘A study on expression of p53 in surface epithelial ovarian tumours’ in MGM Hospital, Warangal. All the ovarian surface epithelial tumour specimens, received in the pathology department during this period were considered. Results: A total of 121 cases were studied, out of which benign tumours were the most common (64.4%), followed by malignancy (25.6%) and 12 cases(10%) of borderline malignancy. Most of the benign tumours were unilateral; the cases that showed bilateral involvement were mostly malignant. The maximum number of cases in the present study was seen in the age group of 31–60 year. The youngest patient was 16 year old and the oldest was 68 year old. Serous cyst adenoma was the most common neoplasm found and accounted for 53 cases (43.8%), followed by mucinous cystadenoma, which accounted for 21 cases (17.3%).Nine cases of serous cystadenofibroma (7.43%), 3 borderline serous tumours (2.47%) and 11 serous cystadenocarcinoma (9%) were found in the present study. Out of the 44 mucinous tumours, 21 were benign (17.3%), 3 were of borderline malignancy (2.47%) and 20 were malignant (16.5%). One case of mucinous cystadenocarcinoma was found to be associated with adenocarcinoma of ascending colon. One case of benign Brenner tumour was also found in the present study. The rate of p53 abnormalities varies with histological type, grade and stage of the tumour. P53 expression was more in malignant serous tumours as compared to the malignant mucinous tumours.
Muir CS, Nectoux J. International patterns of cancer. In: Schottenfeld D, Fraumeni JF, editors. Cancer epidemiology and prevention. 2nd ed.. New York: Oxford University Press; 1996;141–67.
Kristensen GB, Trope C. Epithelial ovarian carcinoma. Lancet 1997;349(9045):113–7.
Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001;27(2):73–9.
Greenblatt MS, Bennett WP, Hollstein M et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855–78.
Kar T, Kar A, Mohapatra PC. Intraoperative cytology of ovarian tumours. J Obstet Gynecol India 2005;55:345–9.
Jha R, Karki S. Histological pattern of ovarian tumors and their age distribution. Nepal Med Coll J 2008;10:81–5.
Maheshwari V, Tyagi SP, Saxena K. Surface epithelial tumours of the ovary. Indian J Pathol Microbiol 1994;37(1):75–85.
Psyrri A, Kountourakis P, YuZ, Papadimitriou C, Markakis S, Camp RL. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets. Annals Oncol 2007;18(4):709–15. doi:10.1093/annonc/mdl479.
P de Graeff, J Hall, A P G Crijns, G H de Bock, JPaul, K A Oien, K A ten Hoor, S de Jong, H Hollema, J M S Bartlett, R Brown, A G J van der Zee Br J Cancer. 2006 Sep 4;95(5):627–633. PMCID:PMC2360689
Ayadi Lobna, Chaabouni Salma, Khabir Abdelmajid et al. World J Oncol 2010;1(3):118–28.
Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51:2979–84.
Kupryjanczyk Jolanta, Thor Ann D, Beauchamp Roberta, Merritt Victor, Edgerton Susan M, Bell Debra A. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993;90:4961–5.
Reles Angela, Wen Wen H, Schmider Annette, Gee Conway, Runnebaum Ingo B. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001;7:2984–97.
Felix CA, Strauss EA, D’Amico D, Tsokos M, WinterS, Mitsudomi T, Nau MM, Brown DL, Leahey AM, Horowitz ME, et al. ... Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet. 1995 Mar;56(3):608.
Murray-Zmijewski F, Slee EA,Lu XA complex barcode underlies the heterogenous response of p53 to stress. Nat Rev Med 2008;9:702–12.
Nat Rev Mol Cell Biol. 2008 Sep;9(9):702-12. doi: 10.1038/nrm2451
Tumour suppressor genes Inactivation of the p53 protein renders it unable to signal and activate the cell’s, Fausto N, Aster J. Robbins & Cotran pathologic basis of disease, 8th edition.
Righetti SC, Della TG, Pilotti S, Menard S, Ottone F, Colnaghi MI.) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689–693
Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR. p53 overexpression is not an independent prognostic factor for patients with
primary ovarian epithelial cancer. Cancer 1997;80:892–898.
Marx D, Meden H, Ziemek T, Lenthe T, Kuhn W, Schauer A. Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur J Cancer 1998;34(6):845–50.
Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Ed- monson JH, Grill. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994;12:64–9.
Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994;53:301–6.
Levesque MA, Katsros D, Yu H, Zola P, Sismondi P, Giatdina Get al.. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer (Philadelphia), 1995;75:1327–38.
Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC, Berchuck A Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 1993;81:643650.
Allan LA, Campbell MK, Milner BJ, Eccles DM, Leonard RCF, Parkin. The significance of p53 mutation and overexpression in ovarian cancer prognosis. Int. J. Gynecol. Cancer 1996;6:483–90.
Sheridan E, Silcocks P, Smith J, Hancock BW, Goyns MH. P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance.Eur J Cancer 1994;30A(11):1701–4.
This work is licensed under a Creative Commons Attribution 3.0 License.
Print ISSN: 2347-6192
Online ISSN: 2347-6206